Search Results - "GOUVERIS, P"

Prognostic role white blood cell levels in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy by Ioannou, A., Demiri, S., Papaxoinis, G., Rapti, V., Klouva, E., Sarris, E., Baxevanos, P., Garefalakis, G., Goumas, G., Gouveris, P., Kourakos, P., Koumakis, G.

Get full text

Carboplatin and paclitaxel in advanced or metastatic endometrial cancer by Pectasides, D, Xiros, N, Papaxoinis, G, Pectasides, E, Sykiotis, C, Koumarianou, A, Psyrri, A, Gaglia, A, Kassanos, D, Gouveris, P, Panayiotidis, J, Fountzilas, G, Economopoulos, T

“…Abstract Objectives The purpose of this study was to evaluate the activity and toxicity of carboplatin and paclitaxel combination in advanced or recurrent…”
Get full text

Molecular profile of head and neck squamous cell carcinomas bearing p16 high phenotype by Rampias, T., Pectasides, E., Prasad, M., Sasaki, C., Gouveris, P., Dimou, A., Kountourakis, P., Perisanidis, C., Burtness, B., Zaramboukas, T., Rimm, D., Fountzilas, G., Psyrri, A.

“…We sought to determine biomarker expression differences in head and neck squamous cell cancers (HNSCCs) based on p16/human papillomavirus (HPV) classification…”
Get full text

Nivolumab‑induced lichenoid granulomatous stomatitis in a patient with advanced melanoma: A case report by Gouveris, P, Georgakopoulou, E.A, Grigoraki, A, Zouki, D.N, Kardara, V.E, Ioannou, S, Tryfonopoulos, D, Demiri, S, Gkouveris, I

“…Lichenoid granulomatous reactions (LGR) are granulomatous inflammations of the skin and oral mucosa, also sharing features of lichenoid lesions. Thus, the…”
Get full text

Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy by GOUVERIS, P, LAZARIS, A. C, PAPATHOMAS, T. G, NONNI, A, KYRIAKOU, V, DELLADETSIMA, J, PATSOURIS, E. S, TSAVARIS, N

“…Our aim was to investigate whether chemotherapy with 5-FU induces an alteration in the levels of topoisomerase I (topo I) in colorectal neoplastic tissues…”
Get full text

Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study by TSAVARIS, N, ZIRAS, N, PAPASTRATIS, G, MARGARIS, H, TSIPRAS, H, POLYZOS, A, KOSMAS, C, GIANNAKAKIS, T, GOUVERIS, P, VADIAKA, M, DIMITRAKOPOULOS, A, KARADIMA, D, ROKANA, S, PAPALAMBROS, E

“…To evaluate the efficacy and safety of irinotecan as second-line treatment in patients with advanced colorectal cancer (ACC) failing or relapsing after…”
Get full text

P-142 Inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy with nab-paclitaxel and gemcitabine: A single-center study by Ioannou, A., Papaxoinis, G., Gouveris, P., Zouki, D., Kardara, V., Ioannou, S., Exarchos, K., Adamou, V., Bitsas, I., Karianakis, G., Koronakis, G., Stavrou, N., Demiri, S.

Get full text

P-145 Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study by Ioannou, S., Papaxoinis, G., Korkolis, D., Kypreos, D., Gouveris, P., Zouki, D., Kardara, V., Exarchos, K., Karianakis, G., Bitsas, I., Adamou, V., Koronakis, G., Stavrou, N., Demiri, S.

Get full text

P-233 Modified FOLFIRINOX as neoadjuvant treatment in patients with borderline resectable and locally advanced pancreatic adenocarcinoma: A single-center study, updated with new data by Ioannou, S., Zouki, D., Kardara, V., Exarchos, K., Arvanitou, E., Gkikas, K., Stavrou, N., Koronakis, G., Tourkantonis, I., Grivas, A., Kourakos, P., Gouveris, P., Kypreos, D., Korkolis, D., Tryfonopoulos, D., Demiri, S., Papaxoinis, G.

Get full text

Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer by Tsavaris, N, Gennatas, K, Kosmas, C, Skopelitis, H M, Gouveris, P, Dimitrakopoulos, A, Zacharakis, M, Kouraklis, G, Vasiliou, J, Felekouras, E, Voros, D, Zografos, G, Balafouta, M, Paraskevaidis, M, Safioleas, M, Fotiadis, K, Papastratis, G, Karatzas, G, Papalambros, E

“…The aim of this study was to evaluate the effectiveness of 6-month therapy with leucovorin (LV) + 5-fluorouracil (5-FU) vs 12 months of therapy with levamisole…”
Get more information

P-292Prognostic role white blood cell levels in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy by Ioannou, A, Demiri, S, Papaxoinis, G, Rapti, V, Klouva, E, Sarris, E, Baxevanos, P, Garefalakis, G, Goumas, G, Gouveris, P, Kourakos, P, Koumakis, G

Get full text

P-223 Prognostic role of inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy by Ioannou, A., Demiri, S., Papaxoinis, G., Sarris, E., Klouva, E., Baxevanos, P., Garefalakis, G., Pitsillos, N., Kyriakidou, A., Mavrogenis, I., Goumas, G., Gouveris, P., Kourakos, P., Trfonopoulos, D., Koumakis, G.

Get full text

Immune changes in patients with colorectal cancer treated by adjuvant therapy with monoclonal antibody 17-1A: a pilot study by Tsitsilonis, O E, Tsavaris, N B, Kosmas, C, Gouveris, P, Papalambros, E

“…We investigated the efficacy of Mo17-1A to improve important immunological parameters in vivo and in vitro in colorectal cancer (CRC) patients receiving no…”
Get full text

1106PPROGNOSIS AND TREATMENT BEYOND PROGRESSION TO BRAF INHIBITORS IN PATIENTS WITH BRAF-MUTATED METASTATIC MELANOMA by Bafaloukos, D., Linardou, H., Tarampikou, A., Gouveris, P., Laskarakis, A., Molfeta, A., Hatzigeorgiou, A., Bousboukea, E., Kanaloupiti, D.

“…Abstract Aim: The treatment of advanced melanoma has dramatically changed with the use of novel targeted and immunotherapeutic agents. Many patients survive…”
Get full text

Prognosis and Treatment Beyond Progression to Braf Inhibitors in Patients with Braf-Mutated Metastatic Melanoma by Bafaloukos, D., Linardou, H., Tarampikou, A., Gouveris, P., Laskarakis, A., Molfeta, A., Hatzigeorgiou, A., Bousboukea, E., Kanaloupiti, D.

Get full text

Impact of human papillomavirus (HPV) E6/E7 gene silencing on the expression of biomarkers that distinguish HPV + versus HPV16 - head and neck squamous cell carcinomas (HNSCC) by Gouveris, P., Rampias, T., Sasaki, C., Psyrri, A.

“…Abstract only e17024 Background: Three studies (Pyeon et al, Slebos et al, and Schlecht et al) have identified biomarkers that distinguish HPV + versus HPV -…”
Get full text

H-RAS and PIK3CA mutations and response to cetuximab in head and neck squamous cell carcinoma (HNSCC) by Rampias, T., Giagini, A., Florou, K., Gouveris, P., Vaja, E., Haralambakis, N., Katsaounis, P., Pectasides, D. G., Economopoulos, T., Psyrri, A.

“…Abstract only…”
Get full text

Evaluation of the incidence and prognostic value of mutant epidermal growth factor receptor (EGFRvIII) protein expression in head and neck squamous cell carcinomas (HNSCC) using AQUA by Pectasides, E., Fountzilas, G., Kountourakis, P., Gouveris, P., Sasaki, C., Duffey, D., Rimm, D., Burtness, B., Psyrri, D.

“…Abstract only…”
Get full text

Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study by Tsavaris, Nicolas, Kosmas, Christos, Skopelitis, Helias, Gouveris, Panagiotis, Kopterides, Petros, Kopteridis, Petros, Loukeris, Dioynissis, Sigala, Frantzeska, Zorbala-Sypsa, Alexandra, Felekouras, Evangelos, Papalambros, Efstathios

“…The present study was conducted to evaluate the efficacy and safety of the combination of Oxaliplatin, Leucovorin and 5-FU as second line therapy, following…”
Get full text

The prognostic value of STAT3 protein in patients with head and neck squamous cell carcinoma (HNSCC) harboring PTEN loss by Fountzilas, G., Pectasides, E., Kountourakis, P., Gouveris, P., Sasaki, C., Duffey, D., Pectasides, D. G., Rimm, D., Burtness, B., Psyrri, D.

“…Abstract only…”
Get full text